NCT02999945

Brief Summary

In this prospective randomized controlled multi center trial the investigators stratify "Very Low Birthweight " (VLBW)-infants with growth retardation in small for gestational age (SGA) or intrauterine growth restricted (IUGR) - infants and aim to investigate the impact of a nutritional management with enhanced nutrients from discharge up to the 52nd week of postconceptional age on growth, body composition, metabolic programming, metabolomics, microbiome and long term neurodevelopmental outcome. In this study, the investigators will evaluate the difference in metabolic profiles of SGA and IUGR preterm infants. The investigators will further longitudinally assess, how different nutritional interventions affect the altered pathways in the first year of life and identify, in combination with data available from metabolic markers, microbiome and breast milk analysis, potential pathways resulting in increased disease risk later in life.

Trial Health

15
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Mar 2019

Typical duration for not_applicable

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 5, 2016

Completed
16 days until next milestone

First Posted

Study publicly available on registry

December 21, 2016

Completed
2.2 years until next milestone

Study Start

First participant enrolled

March 1, 2019

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2020

Completed
2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2022

Completed
Last Updated

March 21, 2019

Status Verified

March 1, 2019

Enrollment Period

10 months

First QC Date

December 5, 2016

Last Update Submit

March 19, 2019

Conditions

Keywords

preterm infantsSGA infantsIUGR infantsgrowthbody compositionmetabolomicsmicrobiomeadiposity markersmetabolic programmingneurodevelopmental outcome

Outcome Measures

Primary Outcomes (1)

  • Fat Free Mass

    Fat free mass measured by body plethysmography

    3 months

Secondary Outcomes (15)

  • anthropometry-length

    24 months

  • anthropometry-weight

    24 months

  • anthropometry-HC

    24 months

  • anthropometry-z-score

    24 months

  • parameters of metabolic programming- IGF1

    12 months

  • +10 more secondary outcomes

Study Arms (4)

SGA-enhanced nutrients

ACTIVE COMPARATOR

Infants will receive fortified breast milk (\>50% meals/d fortified, 1,4 g protein, 85 kcal/100ml, FM85, Nestle ®) or post discharge formula (2g protein; 73-75 kcal/100ml; Aptamil PDF, Milupa® or Beba F Nestle® ) between discharge and 52nd week of gestation (three months after term)

Dietary Supplement: SGA-enhanced nutrients

SGA-standard nutrients

OTHER

Infants will receive unfortified breast milk (65-70kcal/100ml) or starter formula (1,2- 1,3g protein, 66 kcal/100ml Beba Pre Pro Start, Nestle® or Aptamil Pre, Milupa ®) between discharge and 52nd week of gestation (three months after term).

Other: SGA-standard nutrients

IUGR-enhanced nutrients

ACTIVE COMPARATOR

Infants will receive fortified breast milk (\>50% meals/d fortified, 1,4 g protein, 85 kcal/100ml, FM85, Nestle ®) or post discharge formula (2g protein; 73-75 kcal/100ml; Aptamil PDF, Milupa® or Beba F Nestle® ) between discharge and 52nd week of gestation (three months after term

Dietary Supplement: IUGR-enhanced nutrients

IUGR-standard nutrients

OTHER

Infants will receive unfortified breast milk (65-70kcal/100ml) or starter formula (1,2- 1,3g protein, 66 kcal/100ml Beba Pre Pro Start, Nestle® or Aptamil Pre, Milupa ®) between discharge and 52nd week of gestation (three months after term).

Other: IUGR-standard nutrients

Interventions

SGA-enhanced nutrientsDIETARY_SUPPLEMENT

Infants will receive fortified breast milk (\>50% meals/d fortified, 1,4 g protein, 85 kcal/100ml, FM85, Nestle ®) or post discharge formula (2g protein; 73-75 kcal/100ml; Aptamil PDF, Milupa® or Beba F Nestle® ) between discharge and 52nd week of gestation (three months after term

SGA-enhanced nutrients
IUGR-enhanced nutrientsDIETARY_SUPPLEMENT

Infants will receive fortified breast milk (\>50% meals/d fortified, 1,4 g protein, 85 kcal/100ml, FM85, Nestle ®) or post discharge formula (2g protein; 73-75 kcal/100ml; Aptamil PDF, Milupa® or Beba F Nestle® ) between discharge and 52nd week of gestation (three months after term

IUGR-enhanced nutrients

Infants will receive unfortified breast milk (65-70kcal/100ml) or starter formula (1,2- 1,3g protein, 66 kcal/100ml Beba Pre Pro Start, Nestle® or Aptamil Pre, Milupa ®) between discharge and 52nd week of gestation (three months after term)

SGA-standard nutrients

Infants will receive unfortified breast milk (65-70kcal/100ml) or starter formula (1,2- 1,3g protein, 66 kcal/100ml Beba Pre Pro Start, Nestle® or Aptamil Pre, Milupa ®) between discharge and 52nd week of gestation (three months after term)

IUGR-standard nutrients

Eligibility Criteria

AgeUp to 42 Weeks
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17)

You may qualify if:

  • Preterm infants with a birth weight \<1500g and birth weight \<10th percentile.
  • Weight at term \<10th percentile
  • Informed consent

You may not qualify if:

  • Genetic or metabolic diseases with the primary effect on growth
  • Necrotizing enterocolitis
  • Intraventricular hemorrhage (IVH) \>Grade II
  • Periventricular leukomalacia (PVL) Stage III
  • Genetic or metabolic disorders
  • Bronchopulmonary dysplasia

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Failure to ThriveObesityDiabetes MellitusNeurologic Manifestations

Condition Hierarchy (Ancestors)

Signs and SymptomsPathological Conditions, Signs and SymptomsOverweightOvernutritionNutrition DisordersNutritional and Metabolic DiseasesBody WeightGlucose Metabolism DisordersMetabolic DiseasesEndocrine System DiseasesNervous System Diseases

Study Officials

  • Nadja Haiden, MD

    MUW

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assoc. Prof. Dr.

Study Record Dates

First Submitted

December 5, 2016

First Posted

December 21, 2016

Study Start

March 1, 2019

Primary Completion

January 1, 2020

Study Completion

January 1, 2022

Last Updated

March 21, 2019

Record last verified: 2019-03